Literature DB >> 20451637

Immunogenicity and protective efficacy of a recombinant yellow fever vaccine against the murine malarial parasite Plasmodium yoelii.

Cristina T Stoyanov1, Silvia B Boscardin, Stephanie Deroubaix, Giovanna Barba-Spaeth, David Franco, Ruth S Nussenzweig, Michel Nussenzweig, Charles M Rice.   

Abstract

The live-attenuated yellow fever vaccine (YF17D) is one of the safest and most effective vaccines available today. Here, YF17D was genetically altered to express the circumsporozoite protein (CSP) from the murine malarial parasite Plasmodium yoelii. Reconstituted recombinant virus was viable and exhibited robust CSP expression. Immunization of naïve mice resulted in extensive proliferation of adoptively transferred CSP-specific transgenic CD8(+) T-cells. A single immunization of naïve mice with recombinant YF17D resulted in robust production of IFN-gamma by CD8(+) T-cells and IFN-gamma and IL-2 by CD4(+) T-cells. A prime-boost regimen consisting of recombinant virus followed by a low-dose of irradiated sporozoites conferred protection against challenge with P. yoelii. Taken together, these results show that recombinant YF17D can efficiently express CSP in culture, and prime a protective immune response in vivo. (c) 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20451637      PMCID: PMC2935264          DOI: 10.1016/j.vaccine.2010.04.071

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  53 in total

1.  An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow.

Authors:  M B Lutz; N Kukutsch; A L Ogilvie; S Rössner; F Koch; N Romani; G Schuler
Journal:  J Immunol Methods       Date:  1999-02-01       Impact factor: 2.303

2.  Isolation and characterization of protective cytolytic T cells in a rodent malaria model system.

Authors:  P Romero; J L Maryanski; A S Cordey; G Corradin; R S Nussenzweig; F Zavala
Journal:  Immunol Lett       Date:  1990-08       Impact factor: 3.685

3.  Effector functions of circumsporozoite peptide-primed CD4+ T cell clones against Plasmodium yoelii liver stages.

Authors:  L Rénia; D Grillot; M Marussig; G Corradin; F Miltgen; P H Lambert; D Mazier; G Del Giudice
Journal:  J Immunol       Date:  1993-02-15       Impact factor: 5.422

4.  Replication of chimeric yellow fever virus-dengue serotype 1-4 virus vaccine strains in dendritic and hepatic cells.

Authors:  Samantha Brandler; Nathan Brown; Thomas H Ermak; Fred Mitchell; Megan Parsons; Zhenxi Zhang; Jean Lang; Thomas P Monath; Farshad Guirakhoo
Journal:  Am J Trop Med Hyg       Date:  2005-01       Impact factor: 2.345

5.  Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes.

Authors:  Farshad Guirakhoo; Scott Kitchener; Dennis Morrison; Remi Forrat; Karen McCarthy; Richard Nichols; Sutee Yoksan; Xiaochu Duan; Thomas H Ermak; Niranjan Kanesa-Thasan; Philip Bedford; Jean Lang; Marie-Jose Quentin-Millet; Thomas P Monath
Journal:  Hum Vaccin       Date:  2006-03-15

6.  Transcription of infectious yellow fever RNA from full-length cDNA templates produced by in vitro ligation.

Authors:  C M Rice; A Grakoui; R Galler; T J Chambers
Journal:  New Biol       Date:  1989-12

7.  Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial.

Authors:  John J Aponte; Pedro Aide; Montse Renom; Inacio Mandomando; Quique Bassat; Jahit Sacarlal; M Nelia Manaca; Sarah Lafuente; Arnoldo Barbosa; Amanda Leach; Marc Lievens; Johan Vekemans; Betuel Sigauque; Marie-Claude Dubois; Marie-Ange Demoitié; Marla Sillman; Barbara Savarese; John G McNeil; Eusebio Macete; W Ripley Ballou; Joe Cohen; Pedro L Alonso
Journal:  Lancet       Date:  2007-10-18       Impact factor: 79.321

8.  Yellow fever virus replicons as an expression system for hepatitis C virus structural proteins.

Authors:  Richard Molenkamp; Engbert A Kooi; Marjoleine A Lucassen; Sophie Greve; Joyphi C P Thijssen; Willy J M Spaan; Peter J Bredenbeek
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

9.  Elevated gamma interferon-producing NK cells, CD45RO memory-like T cells, and CD4 T cells are associated with protection against malaria infection in pregnancy.

Authors:  Caroline Othoro; Julie M Moore; Kathleen A Wannemuehler; Sichangi Moses; Altaf Lal; Juliana Otieno; Bernard Nahlen; Laurence Slutsker; Ya Ping Shi
Journal:  Infect Immun       Date:  2008-02-04       Impact factor: 3.441

10.  Cytotoxic T cells recognize a peptide from the circumsporozoite protein on malaria-infected hepatocytes.

Authors:  W R Weiss; S Mellouk; R A Houghten; M Sedegah; S Kumar; M F Good; J A Berzofsky; L H Miller; S L Hoffman
Journal:  J Exp Med       Date:  1990-03-01       Impact factor: 14.307

View more
  17 in total

1.  Molecular and immunological characterization of a DNA-launched yellow fever virus 17D infectious clone.

Authors:  Xiaohong Jiang; Tim J Dalebout; Igor S Lukashevich; Peter J Bredenbeek; David Franco
Journal:  J Gen Virol       Date:  2014-12-16       Impact factor: 3.891

2.  Plasmid DNA initiates replication of yellow fever vaccine in vitro and elicits virus-specific immune response in mice.

Authors:  Irina Tretyakova; Brian Nickols; Rachmat Hidajat; Jenny Jokinen; Igor S Lukashevich; Peter Pushko
Journal:  Virology       Date:  2014-08-16       Impact factor: 3.616

Review 3.  The yellow fever 17D virus as a platform for new live attenuated vaccines.

Authors:  Myrna C Bonaldo; Patrícia C Sequeira; Ricardo Galler
Journal:  Hum Vaccin Immunother       Date:  2014-02-19       Impact factor: 3.452

4.  Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs.

Authors:  Xiaohong Jiang; Tim J Dalebout; Peter J Bredenbeek; Ricardo Carrion; Kathleen Brasky; Jean Patterson; Marco Goicochea; Joseph Bryant; Maria S Salvato; Igor S Lukashevich
Journal:  Vaccine       Date:  2010-12-08       Impact factor: 3.641

5.  The live-attenuated yellow fever vaccine 17D induces broad and potent T cell responses against several viral proteins in Indian rhesus macaques--implications for recombinant vaccine design.

Authors:  Philip A Mudd; Shari M Piaskowski; Patricia C Costa Neves; Richard Rudersdorf; Holly L Kolar; Christopher M Eernisse; Kim L Weisgrau; Marlon G Veloso de Santana; Nancy A Wilson; Myrna C Bonaldo; Ricardo Galler; Eva G Rakasz; David I Watkins
Journal:  Immunogenetics       Date:  2010-07-07       Impact factor: 2.846

6.  Identification and characterization of the host protein DNAJC14 as a broadly active flavivirus replication modulator.

Authors:  Zhigang Yi; Lindsey Sperzel; Cindy Nürnberger; Peter J Bredenbeek; Kirk J Lubick; Sonja M Best; Cristina T Stoyanov; Lok Man J Law; Zhenghong Yuan; Charles M Rice; Margaret R MacDonald
Journal:  PLoS Pathog       Date:  2011-01-13       Impact factor: 6.823

Review 7.  Pre-existing immunity against vaccine vectors--friend or foe?

Authors:  Manvendra Saxena; Thi Thu Hao Van; Fiona J Baird; Peter J Coloe; Peter M Smooker
Journal:  Microbiology       Date:  2012-11-22       Impact factor: 2.777

Review 8.  Advanced vaccine candidates for Lassa fever.

Authors:  Igor S Lukashevich
Journal:  Viruses       Date:  2012-10-29       Impact factor: 5.048

9.  Recombinant yellow fever viruses elicit CD8+ T cell responses and protective immunity against Trypanosoma cruzi.

Authors:  Raquel Tayar Nogueira; Alanderson Rocha Nogueira; Mirian Claudia Souza Pereira; Maurício Martins Rodrigues; Patrícia Cristina da Costa Neves; Ricardo Galler; Myrna Cristina Bonaldo
Journal:  PLoS One       Date:  2013-03-19       Impact factor: 3.240

10.  A novel therapeutic HBV vaccine candidate induces strong polyfunctional cytotoxic T cell responses in mice.

Authors:  Robbert Boudewijns; Ji Ma; Johan Neyts; Kai Dallmeier
Journal:  JHEP Rep       Date:  2021-04-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.